On February 25, 2025, Kristen Ambrose, Senior Vice President & Chief Accounting Officer at Vertex Pharmaceuticals Inc (VRTX, Financial), sold 884 shares of the company. Following this transaction, the insider now owns 9,086 shares of Vertex Pharmaceuticals Inc. The details of this transaction can be found in the SEC Filing. Vertex Pharmaceuticals Inc is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company focuses on developing and commercializing therapies for cystic fibrosis and has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta-thalassemia, pain, type 1 diabetes, and alpha-1 antitrypsin deficiency. Over the past year, Kristen Ambrose has sold a total of 3,383 shares and has not purchased any shares. The insider transaction history for Vertex Pharmaceuticals Inc indicates that there have been no insider buys in the past year, while there have been 41 insider sells. On the day of the recent sale, shares of Vertex Pharmaceuticals Inc were trading at $480.95 each, giving the stock a market cap of $123,028.027 million. The stock's GF Value was $419.24, resulting in a price-to-GF-Value ratio of 1.15. This suggests that the stock is modestly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also includes a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
